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Novel oral anticoagulantsAtrial ﬁbrillation (AF) is often accompanied by thrombus in the
left atrium (LA). This thrombus causes thromboembolic complica-
tions. Thus, warfarin has been used for prevention of thromboem-
bolic complications in patients with AF aiming for resolution of LA
thrombus [1,2]. The Japanese guidelines set different target
prothrombin time-international normalized ratios (PT-INRs) for
patients taking warfarin: 1.6–2.6 for elderly patients (70 years)
and 2.0–3.0 for younger patients (<70 years); discordance
between guideline recommendations and real-world clinical
practice is indicated [3]. It has been reported that major bleeding
is observed at PT-INR values above 2.5 on warfarin anticoagulation
[1].
Rivaroxaban is a direct factor Xa inhibitor and belongs to the
class of novel oral anticoagulants (NOACs). Rivaroxaban is reported
to be as efﬁcacious as warfarin in prevention of stroke or systemic
embolism and may cause less bleeding [4]. Relatively few reports
are available regarding the resolution of LA thrombus with NOACs
[5–7].
In this study the authors report a case of an 89-year-old man
who showed AF and a mobile thrombus of 28.6 mm  20.8 mm in
the LA [8]. With the administration of rivaroxaban (10 mg/day) the
thrombus reduced its size and disappeared completely after
2 weeks of rivaroxaban treatment. Because rivaroxaban success-
fully dissolved LA thrombus during a short period, the authors even
suggest that rivaroxaban might have the potential to dissolve
established thrombi by direct inhibition of free and thrombus-
bound coagulation factor Xa in addition to preventing de novo
thrombus formation. The favorable effect of rivaroxaban therapy
on the resolution of LA thrombus provides clinically important
implications of NOACs aimed at resolving thrombus and prevent-
ing thrombus complications.
Formation and resolution of thrombus are based on the balance
between coagulation and ﬁbrinolysis. Rivaroxaban inhibits freeDOI of original article: http://dx.doi.org/10.1016/j.jccase.2014.08.006
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1878-5409  2014 Japanese College of Cardiology. Published by Elsevier Ltd. Open accfactor Xa and prothrombinase activity, and blocks thrombin
generation in a concentration-dependent manner [9], shifting this
balance to ﬁbrinolysis. Reduced thrombin generation contributes
to a loose ﬁbrin clot degradable by proﬁbrinolytic activity
[10]. These phenomena may induce the LA thrombus resolution.
The dose of rivaroxaban (10 mg) adopted in this case is low
as compared with that in the ROCKET AF (rivaroxaban once daily
oral direct factor Xa inhibition compared with vitamin K
antagonist for prevention of stroke and embolism trial in atrial
ﬁbrillation) study (20 mg once daily) [11]. However, a low dose
of rivaroxaban (10 mg once daily) is approved for patients
with renal dysfunction in Japan, and is effective in the resolution
of thrombus. This dose is also consistent with the dose
conducted in the Japanese population (the Japanese-ROCKET AF
study) [4].
Unfortunately the changes in laboratory data for the coagula-
tion and ﬁbrinolytic parameters after rivaroxaban treatment were
not available in this report. We would like to know in this study
whether soluble ﬁbrin and D-dimer levels decreased along with
resolution of LA thrombus without prolongation of PT-INR and
activated partial thromboplastin time. Clearly, further clinical
studies are required on this point. Wada et al. [12] reported that
soluble ﬁbrin and D-dimer levels are useful for diagnosis of
thrombosis. Monitoring of ﬁbrin-related markers such as soluble
ﬁbrin and D-dimer may be helpful in elucidating the mechanism of
favorable effects of NOACs in AF patients. Rivaroxaban treatment
enabled thrombus resolution within a short time. Thus, this NOAC
may have signiﬁcant roles in rhythm control strategies among
similar cases. It is undoubtedly important to investigate further in
a large population whether rivaroxaban and other NOACs are
useful in resolving LA thrombus.
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